Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTQdWlbUUN3ME2wMlA3OSEQvF2= Mmf0V2FPT0WU
ALL-PO MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPyeVQ5UUN3ME2wMlA3OzV3IN88US=> NWT0bmI1W0GQR1XS
697 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrjRmw{UUN3ME2wMlA6QTd4IN88US=> NVzuZpd[W0GQR1XS
NCI-H748 NH7sRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUCzN|Qh|ryP M{fnS3NCVkeHUh?=
NKM-1 NIfkclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMUC5NVIh|ryP MXfTRW5ITVJ?
ES1 NHqzNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1yLkGxNlU2KM7:TR?= MW\TRW5ITVJ?
NCI-H1963 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvJXnlKSzVyPUCuNVE2PzlizszN NH6zeItUSU6JRWK=
NCI-H1417 M2riVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC4ZlZKSzVyPUCuNVI6PzRizszN NFrjRm9USU6JRWK=
NEC8 M{DKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jMdmlEPTB;MD6xN|UzPyEQvF2= NUfkRlVjW0GQR1XS
CRO-AP2 NIjobFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3SSXZsUUN3ME2wMlE3QDh7IN88US=> Ml24V2FPT0WU
A3-KAW MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4naXGlEPTB;MD6xO|YzPyEQvF2= M2XWXHNCVkeHUh?=
SF539 NXPtW3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf0SFlKSzVyPUCuNVk2QTNizszN M3;5TXNCVkeHUh?=
NOS-1 M4XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVZ5RVUUN3ME2wMlE6PjF7IN88US=> Mmj3V2FPT0WU
NTERA-S-cl-D1 NGXkW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O0dGlEPTB;MD6yNFEyOyEQvF2= MVrTRW5ITVJ?
COR-L88 MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPFZZBKSzVyPUCuNlI6PTlizszN M2TU[HNCVkeHUh?=
EM-2 NHTzUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXu[4ZKSzVyPUCuNlQxPzlizszN M3TtSnNCVkeHUh?=
KARPAS-45 NHSzbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPwS2lKSzVyPUCuNlc5OzNizszN Mmm4V2FPT0WU
DSH1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL1OGRQUUN3ME2wMlI5PzB6IN88US=> M4noOHNCVkeHUh?=
HT-144 M171c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\TdYtxUUN3ME2wMlMxOjV4IN88US=> MmHjV2FPT0WU
ATN-1 M1L5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvXWYZKSzVyPUCuN|A2PzZizszN NH3yU|ZUSU6JRWK=
HEL NGfKZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHPXlR3UUN3ME2wMlMyOzR6IN88US=> Ml\2V2FPT0WU
NB12 NE\HcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fQSWlEPTB;MD6zNVc2PiEQvF2= M3PucnNCVkeHUh?=
LU-139 NHnFV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13VOmlEPTB;MD6zN|UyKM7:TR?= NFrpOFZUSU6JRWK=
J-RT3-T3-5 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPpbGRKSzVyPUCuN|M4OTZizszN NUjpSlZlW0GQR1XS
MOLT-13 NIjPN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jiR2lEPTB;MD6zN|gyKM7:TR?= MWDTRW5ITVJ?
SR M1L1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTeWlEPTB;MD6zOFI3OSEQvF2= MX3TRW5ITVJ?
CMK MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD1yLkO1O|I4KM7:TR?= NWHOfHl1W0GQR1XS
ES8 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M370S2lEPTB;MD6zOlAzOiEQvF2= M3qzVXNCVkeHUh?=
LB647-SCLC NUS5VW1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnKRnpuUUN3ME2wMlM3PzNizszN Ml;DV2FPT0WU
TE-8 M4PmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwM{[5N|Uh|ryP NUjzN2hkW0GQR1XS
BV-173 NV\1bFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHUTWM2OD1yLkO3NVIyKM7:TR?= M1jNXXNCVkeHUh?=
DEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT4em1KSzVyPUCuN|c1QDdizszN NWr1c2F2W0GQR1XS
ARH-77 NF2xbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrtTWM2OD1yLkO4NVk{KM7:TR?= MlnXV2FPT0WU
NCCIT NXm3e2lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrGPJlKSzVyPUCuN|g3PDlizszN NXXV[Y0yW0GQR1XS
RPMI-8402 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrETWM2OD1yLkO4O|AyKM7:TR?= NYC2eZRRW0GQR1XS
MONO-MAC-6 NFHzbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwM{i3O|Yh|ryP NVuzNWl2W0GQR1XS
SK-MM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XaNGlEPTB;MD6zPVg3QCEQvF2= MW\TRW5ITVJ?
CHP-126 NVP4[G9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNECyN|Eh|ryP NY\JR5g6W0GQR1XS
A101D M1zsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNECzJO69VQ>? MlnvV2FPT0WU
SCH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNECzOFIh|ryP MoPOV2FPT0WU
NMC-G1 NULkSIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwNECzOlch|ryP MW\TRW5ITVJ?
NCI-H209 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\zdZREUUN3ME2wMlQxPjF|IN88US=> NW\uWZVuW0GQR1XS
MOLT-16 M4DmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNEGwNVch|ryP MX;TRW5ITVJ?
RPMI-6666 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNEGxNkDPxE1? MVPTRW5ITVJ?
OPM-2 M{jaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwNEG1NVMh|ryP NIPmSZVUSU6JRWK=
MRK-nu-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT5TWM2OD1yLkSzNVU{KM7:TR?= MVnTRW5ITVJ?
BC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmzO|NFUUN3ME2wMlQ{PDB|IN88US=> Mnv3V2FPT0WU
MHH-NB-11 M2LXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n4fGlEPTB;MD60N|Q2OyEQvF2= M1W4PHNCVkeHUh?=
Ramos-2G6-4C10 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H0WWlEPTB;MD60N|g6PyEQvF2= M{\3RXNCVkeHUh?=
LS-513 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXpS|FsUUN3ME2wMlQ1PTBzIN88US=> MXjTRW5ITVJ?
K5 M2j2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4SopZUUN3ME2wMlQ4ODJ3IN88US=> M1nGTHNCVkeHUh?=
HOP-62 M4\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnNSmpKSzVyPUCuOFg{PThizszN NILUS3NUSU6JRWK=
NCI-H187 NFLBTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LndGlEPTB;MD60PVIzPyEQvF2= Mor3V2FPT0WU
BE-13 NVz3[WROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nJSGlEPTB;MD60PVY3OSEQvF2= MXPTRW5ITVJ?
HC-1 NVPJTJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNUC0O|Mh|ryP MVnTRW5ITVJ?
ACN NWHHSY4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD1yLkWxNFI5KM7:TR?= MVfTRW5ITVJ?
HCC1599 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwNUG1O{DPxE1? NUPFfnlrW0GQR1XS
MV-4-11 M{fVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7lTWM2OD1yLkWzNFQyKM7:TR?= MVjTRW5ITVJ?
LC-2-ad NH32OFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwNUO2OlMh|ryP MXjTRW5ITVJ?
HL-60 NYTLOHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnSOY1KSzVyPUCuOVQzPjFizszN M135SnNCVkeHUh?=
NB17 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;2T2ZKSzVyPUCuOVQ{QCEQvF2= MWPTRW5ITVJ?
TE-1 M{Dy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfC[IRvUUN3ME2wMlU2OzB4IN88US=> MVTTRW5ITVJ?
NCI-H524 NWfjOFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNUW0NFEh|ryP M1XpVHNCVkeHUh?=
MZ7-mel NYfrc3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNU[xNFUh|ryP NVu0eHFFW0GQR1XS
L-363 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPFTWM2OD1yLkW2OlU4KM7:TR?= NWjJRo9QW0GQR1XS
BL-41 NXr2TJpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXyTWM2OD1yLkW2PFg6KM7:TR?= NVm2NGx7W0GQR1XS
LU-134-A NI\w[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjTWM2OD1yLkW3NFc{KM7:TR?= Mo\BV2FPT0WU
SIG-M5 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojUTWM2OD1yLkW3PFQ5KM7:TR?= NWmzTpI1W0GQR1XS
ONS-76 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwNUiyOFIh|ryP MXnTRW5ITVJ?
KARPAS-299 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rKfWlEPTB;MD61PFUxPCEQvF2= NV7XeGloW0GQR1XS
DU-4475 NUXUSWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXwZVlZUUN3ME2wMlU5PzB|IN88US=> MoLGV2FPT0WU
NB69 M1mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3HZWc2UUN3ME2wMlU6QDJ3IN88US=> MVXTRW5ITVJ?
MHH-PREB-1 M1L1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNkC3NVkh|ryP MYDTRW5ITVJ?
LU-165 M4PuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNkG4NVIh|ryP MkLIV2FPT0WU
LOUCY NXnZc4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DmV2lEPTB;MD62N|M3PCEQvF2= Mlz4V2FPT0WU
NCI-H526 NEHjR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf4eGNbUUN3ME2wMlY{PTRzIN88US=> MUTTRW5ITVJ?
KE-37 NIPGV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6PGhWUUN3ME2wMlY1Ojd4IN88US=> MWnTRW5ITVJ?
NALM-6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1ZXBKSzVyPUCuOlQ5PiEQvF2= Ml2zV2FPT0WU
CW-2 M{nEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHZUnFKSzVyPUCuOlU4QTRizszN Mo\JV2FPT0WU
SU-DHL-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DxUGlEPTB;MD62OVk1PyEQvF2= Mo\1V2FPT0WU
NB13 M2TTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HTU2lEPTB;MD62OlgyPyEQvF2= MU\TRW5ITVJ?
QIMR-WIL NFPQT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTDTWM2OD1yLk[4N|Q{KM7:TR?= M2\HT3NCVkeHUh?=
ECC12 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\pZmZKUUN3ME2wMlcxODh4IN88US=> NUDDSo1uW0GQR1XS
KALS-1 NHvuU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC2cGdKSzVyPUCuO|A1QTJizszN MWPTRW5ITVJ?
COR-L279 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:zTWM2OD1yLkewPVk3KM7:TR?= NHGwUGRUSU6JRWK=
NB14 NXLSUZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf1eHpKSzVyPUCuO|I3OTdizszN MX;TRW5ITVJ?
CCRF-CEM NV7sPWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHvSI9KSzVyPUCuO|Q3PjFizszN MmXNV2FPT0WU
SW954 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176XGlEPTB;MD63OVk6QSEQvF2= NEHuclFUSU6JRWK=
IST-SL1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXicmJKSzVyPUCuO|c{PDhizszN Mo[yV2FPT0WU
LAMA-84 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwN{e1Olch|ryP NE\oSI1USU6JRWK=
Daudi NGW4ephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjW[JhzUUN3ME2wMlc4PjhzIN88US=> Mm\mV2FPT0WU
BC-3 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfzTWM2OD1yLke4N|A5KM7:TR?= NWjlOYhYW0GQR1XS
HCC2998 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqdHA4UUN3ME2wMlc5OzZizszN NXjWXY06W0GQR1XS
NCI-H69 NU[5bFNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPpTIZKSzVyPUCuPFAyPDdizszN NXrMZog4W0GQR1XS
CPC-N NVm0SmtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\acmlEPTB;MD64NFUzPCEQvF2= MmqzV2FPT0WU
NOMO-1 NFHneZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXPeZVKSzVyPUCuPFExQDRizszN MX;TRW5ITVJ?
CESS MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOEGxPVch|ryP M{PtbXNCVkeHUh?=
LC4-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7FTWM2OD1yLki0NFA4KM7:TR?= MmezV2FPT0WU
BL-70 M3L6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L5eWlEPTB;MD64OVcxOiEQvF2= MYXTRW5ITVJ?
ES4 M3TEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJZo5KSzVyPUCuPFU5PjhizszN NWXIbYU6W0GQR1XS
HCE-T NF\oXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lkc2lEPTB;MD64O|E4OSEQvF2= Mnj1V2FPT0WU
JAR NXzzclRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOEe4Nlch|ryP M{D3eHNCVkeHUh?=
ST486 M3jTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LrR2lEPTB;MD64O|kyPyEQvF2= MWnTRW5ITVJ?
KS-1 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH0TWM2OD1yLki4NFk3KM7:TR?= M3fkSnNCVkeHUh?=
GDM-1 M4fSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD1yLki4Olg4KM7:TR?= MVjTRW5ITVJ?
EHEB MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH0U3lKSzVyPUCuPVI2QDVizszN MXLTRW5ITVJ?
LB2518-MEL MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;HSYZKSzVyPUCuPVMzQDRizszN NGPjSHVUSU6JRWK=
GOTO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX3PYRKSzVyPUCuPVUxPzZizszN MmLkV2FPT0WU
LXF-289 NX;OUYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLkTWM2OD1yLkm1PVAyKM7:TR?= Mlm1V2FPT0WU
ES6 M2rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiwUHlKSzVyPUCuPVY1OzdizszN MXjTRW5ITVJ?
OS-RC-2 M1zMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX4TWM2OD1yLkm2PFMh|ryP Mn\VV2FPT0WU
DMS-153 M{PQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwOUe0Olkh|ryP M4mwRXNCVkeHUh?=
SK-PN-DW NEjNS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfvTWM2OD1yLkm3PFMyKM7:TR?= MmDIV2FPT0WU
HH NIro[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nw[2lEPTB;MD65PFk2QSEQvF2= M3rXU3NCVkeHUh?=
SH-4 M3;KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMEK0NUDPxE1? NVz0SXE6W0GQR1XS
MOLT-4 NF2zbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHQfVJKSzVyPUGuNFM1PTRizszN NYL3NY5rW0GQR1XS
TGW M2PUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMEe2O|Uh|ryP NGjKN3BUSU6JRWK=
L-540 M2exSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXVN2FKSzVyPUGuNVA3ODRizszN MYnTRW5ITVJ?
PF-382 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwenFnUUN3ME2xMlEyPTF|IN88US=> NYfOXGZIW0GQR1XS
LC-1F NHm2UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXOe|FKSzVyPUGuNVIxODdizszN MV;TRW5ITVJ?
OVCAR-4 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLXSZNRUUN3ME2xMlE{OTZ3IN88US=> MX;TRW5ITVJ?
A4-Fuk NIfSV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMUWzOlQh|ryP MULTRW5ITVJ?
HCC2218 NWLmWIV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknzTWM2OD1zLkG2OlQyKM7:TR?= Mnu3V2FPT0WU
HAL-01 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfYTWM2OD1zLkG2PVQ{KM7:TR?= NV7wSHROW0GQR1XS
IST-MEL1 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfofm5KSzVyPUGuNVc3PTlizszN M{G2O3NCVkeHUh?=
NCI-H719 M1PtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXBTWM2OD1zLkG3PFk5KM7:TR?= NGnqSmdUSU6JRWK=
EVSA-T NF7UUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMUixNVQh|ryP NX;KO5hJW0GQR1XS
SK-NEP-1 NV21XIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjLSm1KSzVyPUGuNlAzPjZizszN NYK2c|F4W0GQR1XS
OCUB-M NGW1R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1zLkKxOFg6KM7:TR?= MXHTRW5ITVJ?
MEG-01 NHK3SYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMkKxNVgh|ryP NGmxUolUSU6JRWK=
no-10 NEXtVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITkfnRKSzVyPUGuNlMyOTJizszN M3[5ZXNCVkeHUh?=
MHH-CALL-2 M2\ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[wTWM2OD1zLkK0O|IyKM7:TR?= M2LBW3NCVkeHUh?=
SK-N-DZ NIPublhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLjdIgyUUN3ME2xMlI1Pzd4IN88US=> MY\TRW5ITVJ?
SCLC-21H NULB[4hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ETWM2OD1zLkK2OFc5KM7:TR?= MkG4V2FPT0WU
CTV-1 NEDzTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPHd3dKSzVyPUGuNlc1OjVizszN M2PRbnNCVkeHUh?=
NB1 M3Xub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W4dGlEPTB;MT6yO|c{OiEQvF2= MlfoV2FPT0WU
NCI-H64 NU\zW4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFwMki0OlIh|ryP MkXGV2FPT0WU
MDA-MB-134-VI NX;YTGxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMki1O|ch|ryP M1r4[nNCVkeHUh?=
LB2241-RCC MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMki2OlMh|ryP NFLnUW5USU6JRWK=
8-MG-BA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXDWFhSUUN3ME2xMlI5QDZ4IN88US=> NHvxOlVUSU6JRWK=
LP-1 M1v0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwMkm5OFch|ryP MmLLV2FPT0WU
LS-411N NF;JcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT4TWM2OD1zLkOwPVk5KM7:TR?= NX;JflJDW0GQR1XS
CAL-148 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j4VGlEPTB;MT6zNlU1OiEQvF2= M4nVXXNCVkeHUh?=
NCI-H2171 NXr4ZlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHSxV29KSzVyPUGuN|Q2ODJizszN NF6yfndUSU6JRWK=
JiyoyeP-2003 NHn2eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwM{WzPUDPxE1? MXnTRW5ITVJ?
NCI-H2107 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwM{W4PFMh|ryP MmfyV2FPT0WU
BB30-HNC NEX6UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwM{i5O|gh|ryP MVXTRW5ITVJ?
K-562 NXe2XItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwM{myNVkh|ryP MYPTRW5ITVJ?
PSN1 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPZeXRrUUN3ME2xMlQzOjh5IN88US=> MVTTRW5ITVJ?
HCC2157 NHvGXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzqVYNKSzVyPUGuOFI3QTFizszN MVzTRW5ITVJ?
SBC-1 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nkbGlEPTB;MT60Nlc1OSEQvF2= NEDRdnVUSU6JRWK=
MC116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1zLkSzOlE2KM7:TR?= M2Xk[3NCVkeHUh?=
KARPAS-422 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzseGFKSzVyPUGuOFU{PThizszN NWmzR2tMW0GQR1XS
LB996-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwNEexNFMh|ryP MV\TRW5ITVJ?
MSTO-211H Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwNEe5PFch|ryP M2PlWXNCVkeHUh?=
BT-474 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNUG3OlQh|ryP M4O5UXNCVkeHUh?=
A388 NHTDfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3KTWM2OD1zLkWxPVQ2KM7:TR?= MUjTRW5ITVJ?
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D4[2lEPTB;MT61NlI3KM7:TR?= MYXTRW5ITVJ?
COLO-829 NHjBepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjJOopJUUN3ME2xMlU{PTZ2IN88US=> M{fpdXNCVkeHUh?=
KM-H2 NVHEb|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOy[ItKSzVyPUGuOVY3PyEQvF2= MYrTRW5ITVJ?
GR-ST MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwNU[4NkDPxE1? NGDCUIhUSU6JRWK=
RPMI-8866 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;1OHB4UUN3ME2xMlYxOTR2IN88US=> NITseZNUSU6JRWK=
KG-1 NGnCSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT4O3V3UUN3ME2xMlYyQTBzIN88US=> MluyV2FPT0WU
NCI-H82 Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj4TWM2OD1zLk[zOFA3KM7:TR?= NETlV2pUSU6JRWK=
LB1047-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxcGlEPTB;MT62N|Q2QSEQvF2= NUPHSHViW0GQR1XS
KM12 NYXKUVJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwNkS3JO69VQ>? MnLiV2FPT0WU
NB5 M2TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWwdHpKSzVyPUGuOlU3PzdizszN MVzTRW5ITVJ?
HDLM-2 NWO4Npo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrjPWhKSzVyPUGuOlgzQDFizszN NEjYeYZUSU6JRWK=
KU812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrvTWM2OD1zLk[5OlA2KM7:TR?= MUHTRW5ITVJ?
DB M1PC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:xOmlEPTB;MT63NFM2OyEQvF2= NHjNeWhUSU6JRWK=
HD-MY-Z NHrhRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPFTWM2OD1zLke1NlM1KM7:TR?= MmLiV2FPT0WU
KURAMOCHI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7yTWM2OD1zLke3NlA4KM7:TR?= NVyxd4pUW0GQR1XS
ETK-1 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1roR2lEPTB;MT63PFg4QSEQvF2= M4Pn[XNCVkeHUh?=
SK-UT-1 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwN{mzPFgh|ryP MWLTRW5ITVJ?
HUTU-80 NH7nZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofrTWM2OD1zLke5OVA5KM7:TR?= M2fUOHNCVkeHUh?=
ES7 M1X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1zLkiwN|AzKM7:TR?= NIPINZJUSU6JRWK=
SW872 NVvqWIZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nkN2lEPTB;MT64NVM6PSEQvF2= M1T2VHNCVkeHUh?=
TK10 NFL0bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LVTmlEPTB;MT64N|ExQCEQvF2= MoLOV2FPT0WU
LB831-BLC NWrrO3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwOEO1OlMh|ryP MlLLV2FPT0WU
TE-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljSTWM2OD1zLki0OFIzKM7:TR?= MYnTRW5ITVJ?
MLMA NH\H[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH1WYhKSzVyPUGuPFgzOzRizszN M1:2cHNCVkeHUh?=
D-542MG MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwOEmzO|Mh|ryP NG\RbJVUSU6JRWK=
EW-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfhVYNYUUN3ME2xMlkzPzJizszN MVHTRW5ITVJ?
LOXIMVI MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjB[nFKSzVyPUGuPVMzQCEQvF2= NEPscpFUSU6JRWK=
GB-1 NHruTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fDO2lEPTB;MT65N|g3PiEQvF2= MmDvV2FPT0WU
IST-SL2 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDVTWM2OD1{LkCwNlYzKM7:TR?= MXXTRW5ITVJ?
LAN-6 NEnrPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lld2lEPTB;Mj6wNVk3PiEQvF2= NEjhfmZUSU6JRWK=
NCI-H510A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTiTWM2OD1{LkC0OVAzKM7:TR?= NWDhRYVCW0GQR1XS
NCI-H1092 M2\0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K2d2lEPTB;Mj6wOVEzPCEQvF2= MYTTRW5ITVJ?
HT M1exXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7xTpE3UUN3ME2yMlExPDV2IN88US=> MoPGV2FPT0WU
RL95-2 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXZUpRKSzVyPUKuNVE1QDJizszN M2\WenNCVkeHUh?=
NCI-H1355 M4nJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjuSY9WUUN3ME2yMlEyPzl{IN88US=> NGHoSVFUSU6JRWK=
NCI-H720 M{TaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XhcGlEPTB;Mj6xOlg4OyEQvF2= MnjqV2FPT0WU
NCI-H1522 NWL0XXZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zQUWlEPTB;Mj6yNVczOyEQvF2= MnT4V2FPT0WU
LB373-MEL-D MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknHTWM2OD1{LkK2PVAzKM7:TR?= MXHTRW5ITVJ?
DG-75 M1K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3FfFhWUUN3ME2yMlI4OTR6IN88US=> NH3Pe5RUSU6JRWK=
ML-2 M1XUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3exb2lEPTB;Mj6zNlg2PSEQvF2= NVLrNppLW0GQR1XS
SF126 NF\qN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ISpNKSzVyPUKuN|MxQTRizszN NFryWmxUSU6JRWK=
MPP-89 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrBb3NKSzVyPUKuN|MyPDVizszN MX3TRW5ITVJ?
NCI-H345 NXXpUmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwM{OyO|ch|ryP MkTDV2FPT0WU
LS-123 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7BRZRIUUN3ME2yMlM1QTN4IN88US=> M1nJdnNCVkeHUh?=
NB10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq3dlZKSzVyPUKuOFExQTJizszN MX7TRW5ITVJ?
CGTH-W-1 NXPwTZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;BWI57UUN3ME2yMlQzOjZ5IN88US=> MWnTRW5ITVJ?
CP66-MEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfUTWM2OD1{LkS3O|ch|ryP NXT5Sm1TW0GQR1XS
L-428 NGrtOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS1OmRKSzVyPUKuOFg2OjFizszN NEHMS4pUSU6JRWK=
DMS-79 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTwTm9NUUN3ME2yMlU1OTB|IN88US=> MlG0V2FPT0WU
NCI-H1882 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwNke1OlIh|ryP MUPTRW5ITVJ?
KGN MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwN{[4O|Yh|ryP MkfDV2FPT0WU
EW-1 M2P4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOxTWM2OD1{Lke3NFg{KM7:TR?= MmjvV2FPT0WU
U-266 M3jM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPmdlFKSzVyPUKuPFQ5OjNizszN Mlj0V2FPT0WU
COLO-320-HSR M1LEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwOEW2OFEh|ryP Mn3sV2FPT0WU
KMOE-2 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrqVHNVUUN3ME2yMlg4PzFzIN88US=> M4GxeHNCVkeHUh?=
BB49-HNC NXX6WmVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfUeIhKSzVyPUKuPVI1QCEQvF2= MkDJV2FPT0WU
GI-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m2S2lEPTB;Mj65Nlk2PyEQvF2= Ml72V2FPT0WU
NCI-H1304 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfBNYhrUUN3ME2zMlAxPTFzIN88US=> MlnXV2FPT0WU
NCI-H2227 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL3RolQUUN3ME2zMlAzODd7IN88US=> M4DUWXNCVkeHUh?=
U-87-MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6UHBKSzVyPUOuNFM2OTNizszN MUTTRW5ITVJ?
NCI-H747 NXvV[YNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH4TWM2OD1|LkC1NlA3KM7:TR?= M{myOnNCVkeHUh?=
CTB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK1TWM2OD1|LkC1N|c3KM7:TR?= NXLHNGNlW0GQR1XS
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXITWM2OD1|LkG0N|c5KM7:TR?= NHnTVVRUSU6JRWK=
NCI-H2141 M4P2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHMOVdKSzVyPUOuNVY2PjZizszN NIfmSI5USU6JRWK=
IST-MES1 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G1emlEPTB;Mz6xPFI4QSEQvF2= NVvYeGtNW0GQR1XS
TE-5 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjCWnFKSzVyPUOuNlE{PDJizszN NFzp[pNUSU6JRWK=
UACC-257 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5T2lEPTB;Mz60N|Y2QSEQvF2= M{T6VnNCVkeHUh?=
SK-N-FI MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGeyOmlKSzVyPUOuOFUzOjdizszN MnHIV2FPT0WU
MFH-ino MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LhbWlEPTB;Mz60OlU5QSEQvF2= NGTTc2xUSU6JRWK=
SF268 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jIR2lEPTB;Mz60PFE4PCEQvF2= MUfTRW5ITVJ?
TE-12 M3[1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HaZWlEPTB;Mz61NVY6QSEQvF2= NHLyfIJUSU6JRWK=
NB6 NWTjU3lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;WW2lEPTB;Mz61OVU3OyEQvF2= NWjDcGNyW0GQR1XS
DJM-1 M3zRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwNUm4PVkh|ryP NHTBbWVUSU6JRWK=
MZ1-PC M3rYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHUfJNHUUN3ME2zMlYyPjJ2IN88US=> MVTTRW5ITVJ?
OCI-AML2 MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrXTWM2OD1|Lk[yOlcyKM7:TR?= Moe2V2FPT0WU
NCI-H1155 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNwN{C5OFch|ryP NWPKOZBiW0GQR1XS
RKO NUjHeGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\WblVKSzVyPUOuO|cyQDlizszN MWnTRW5ITVJ?
ECC4 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPrd3hGUUN3ME2zMlk4OTl3IN88US=> MWrTRW5ITVJ?
BB65-RCC NFrjfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1|Lkm3OVQ4KM7:TR?= MoHIV2FPT0WU
EB-3 M4THbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\SNmlEPTB;Mz65PVY{OyEQvF2= M3zS[3NCVkeHUh?=
SHP-77 NHrDS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwMEC1NlQh|ryP M1rzOXNCVkeHUh?=
NCI-H2196 NGjodphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknJTWM2OD12LkC1OlI2KM7:TR?= MVjTRW5ITVJ?
GI-ME-N MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e4fGlEPTB;ND6wOlM6QSEQvF2= NVjoOo9QW0GQR1XS
MN-60 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu5NZFKSzVyPUSuNVA5PyEQvF2= MVrTRW5ITVJ?
NCI-H1694 NGHCZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD5XmtQUUN3ME20MlE{PDB3IN88US=> MWfTRW5ITVJ?
LU-65 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq1RVhKSzVyPUSuNVU{OzJizszN NVTDOoU6W0GQR1XS
NCI-H1436 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljJTWM2OD12LkG4N|M{KM7:TR?= NF3YXoFUSU6JRWK=
KINGS-1 NVTyN|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD12LkOxOFMzKM7:TR?= NWnlbHkyW0GQR1XS
GT3TKB NXrHT5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz2TWM2OD12LkOzNlY5KM7:TR?= MnnMV2FPT0WU
Becker M4fsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwM{ezNVIh|ryP NF7jbpBUSU6JRWK=
HCC1187 NFjjb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq5SHpRUUN3ME20Mlg6PjV5IN88US=> MW\TRW5ITVJ?
D-502MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwMEC0NVYh|ryP Mkf1V2FPT0WU
VA-ES-BJ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XMVGlEPTB;NT6xN|c4QCEQvF2= NX60NmdXW0GQR1XS
NB7 M3:5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxOWlEPTB;NT6xOFEyOiEQvF2= M2DTNHNCVkeHUh?=
SW962 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwM{i4NVQh|ryP NHrrR3JUSU6JRWK=
no-11 M1HXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfiV5VKSzVyPUWuO|Y{PDNizszN M2HjTHNCVkeHUh?=
KNS-81-FD NGTBOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnVUItKSzVyPUWuPVA3QTRizszN M13VZ3NCVkeHUh?=
COLO-684 NF;afplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nHUmlEPTB;NT65PVQ6PCEQvF2= NXGxc|l[W0GQR1XS
D-263MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zPbmlEPTB;Nj6wPFg6PSEQvF2= NIH0NnBUSU6JRWK=
EW-24 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTuNHIxUUN3ME22MlI5PTFizszN NVnhdGJkW0GQR1XS
TE-10 NFviNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nj[mlEPTB;Nj60NlYzOyEQvF2= M{XYUnNCVkeHUh?=
EKVX MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP3TWM2OD14LkS2N|IyKM7:TR?= MmXMV2FPT0WU
NCI-H1648 M{DlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KzcmlEPTB;Nj62O|U2PyEQvF2= M3jGVXNCVkeHUh?=
LB771-HNC MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTpTWM2OD14LkmyN|AyKM7:TR?= MnfiV2FPT0WU
SK-MEL-1 M2iybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRThwMUOxOlYh|ryP M2nrfnNCVkeHUh?=
COLO-668 NHe0fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;zfmNKSzVyPUiuNlc4QDZizszN M3y2SHNCVkeHUh?=
EW-12 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwNEC4NFMh|ryP MojqV2FPT0WU
A253 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1NG5KSzVyPUiuPFQ3PjFizszN NGTwOnZUSU6JRWK=
NCI-H2126 M1jyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HtTWlEPTB;OD64PVMyQSEQvF2= MY\TRW5ITVJ?
Calu-6 NGHwbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjNe45QUUN3ME24Mlk6ODR{IN88US=> NInkW4dUSU6JRWK=
NCI-H23 M4PJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjYNGM{UUN3ME25MlE4PzR4IN88US=> MoLCV2FPT0WU
WSU-NHL NWf5NVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7veIJKSzVyPUmuO|c1PzhizszN M{Pkd3NCVkeHUh?=
MMAC-SF MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwOUe5NFQh|ryP MW\TRW5ITVJ?
SK-LMS-1 NEH1O3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm5ZWxrUUN3ME2xNE4zQDN2IN88US=> NGHWRndUSU6JRWK=
GCIY NEj6cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLkW5NlQh|ryP MUXTRW5ITVJ?
TE-15 NGS2e|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLk[wNFQh|ryP NVfIUINtW0GQR1XS
EoL-1-cell MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3VbHFKSzVyPUGxMlc3QDJizszN M2j0RXNCVkeHUh?=
NCI-H2081 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFzLke3PFYh|ryP Mk\sV2FPT0WU
EW-3 NI[4bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLn[XpKSzVyPUGyMlI1PjNizszN NVrw[|ZTW0GQR1XS
CAS-1 NWXp[GRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLMcIxKSzVyPUGyMlM3OzFizszN MXfTRW5ITVJ?
C2BBe1 NH;kWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfXNphKSzVyPUGyMlYyOzFizszN NXPrVnJEW0GQR1XS
D-247MG M1zZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rQe2lEPTB;MUKuO|k2OiEQvF2= NGrBe|JUSU6JRWK=
NCI-SNU-5 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF{LkiwNVMh|ryP MnnXV2FPT0WU
LS-1034 NWO2[ZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF2LkO5O|Uh|ryP NYHHdWxWW0GQR1XS
EW-18 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrRWFJKSzVyPUG0MlQ1QCEQvF2= MYPTRW5ITVJ?
Raji MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF2LkWwOFkh|ryP M2XkcnNCVkeHUh?=
D-283MED MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD1zND62NlcyKM7:TR?= NWqzV3BiW0GQR1XS
MZ2-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DmdWlEPTB;MUSuPVY6PiEQvF2= MWrTRW5ITVJ?
NCI-SNU-16 NHf4WmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF3LkS2N|Mh|ryP M3zuNHNCVkeHUh?=
P30-OHK NF7ueXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF5Lke4N|Eh|ryP MVrTRW5ITVJ?
RXF393 M{i2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF7LkCxPFYh|ryP NXvueGR5W0GQR1XS
NCI-H1395 NVX5RmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDXPXBKSzVyPUKwMlY4ODNizszN NXfabZZYW0GQR1XS
U-698-M NGjsXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILsXlBKSzVyPUKwMlcxPzVizszN NGP0U4pUSU6JRWK=
NCI-SNU-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L6V2lEPTB;MkCuO|IzOyEQvF2= M3\6NXNCVkeHUh?=
SW684 NGnHSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJzLkG3NVYh|ryP M1LsXXNCVkeHUh?=
NCI-H716 NHHVOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPsTWM2OD1{MT6zNVU1KM7:TR?= MXXTRW5ITVJ?
JVM-2 NGftOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLQTWM2OD1{MT60NVM{KM7:TR?= MlHWV2FPT0WU
NCI-H1581 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrQXHFKSzVyPUKyMlQyPDhizszN MX;TRW5ITVJ?
CA46 NF\CO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jkW2lEPTB;M{GuOlk{PiEQvF2= NWL5c5RXW0GQR1XS
SNB75 NXPpNnVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDUb29DUUN3ME2zN{43PTB|IN88US=> MX\TRW5ITVJ?
KNS-42 NXO3TpE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXybWhYUUN3ME2zOU46PjJ2IN88US=> NFS3XJVUSU6JRWK=
TUR M{OxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnNOVFmUUN3ME2zOk4xPTJzIN88US=> Mm[3V2FPT0WU
REH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvEUG83UUN3ME2zO{45OjFzIN88US=> M3HyfXNCVkeHUh?=
EW-22 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rOcWlEPTB;NEKuNlg5PSEQvF2= NYXwb4JqW0GQR1XS
NCI-H446 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR{Lke4OVMh|ryP NWjLWWZnW0GQR1XS
ES3 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nsfWlEPTB;NEOuNVM{QSEQvF2= NGHifW5USU6JRWK=
EW-11 NXHoNpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XCTmlEPTB;NESuPFIyQCEQvF2= M{LWZnNCVkeHUh?=
RH-1 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPSTWM2OD12Nz61PFEzKM7:TR?= M3rYNnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay
+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research
+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02780804 Not yet recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) March 2017 Phase 1
NCT02833155 Not yet recruiting Breast Cancer EddingPharm Oncology Co., LTD. July 2016 Phase 1
NCT02820961 Recruiting Breast Cancer|Estrogen Receptor Positive Breast Cancer Syndax Pharmaceuticals June 2016 Phase 1
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 2016 Phase 2
NCT02708680 Not yet recruiting Breast Cancer Syndax Pharmaceuticals|Roche Pharma AG April 2016 Phase 1|Phase 2
NCT02453620 Recruiting Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Solid Neoplasm|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer National Cancer Institute (NCI) November 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID